BR112021023901A2 - Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer - Google Patents

Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer

Info

Publication number
BR112021023901A2
BR112021023901A2 BR112021023901A BR112021023901A BR112021023901A2 BR 112021023901 A2 BR112021023901 A2 BR 112021023901A2 BR 112021023901 A BR112021023901 A BR 112021023901A BR 112021023901 A BR112021023901 A BR 112021023901A BR 112021023901 A2 BR112021023901 A2 BR 112021023901A2
Authority
BR
Brazil
Prior art keywords
drug conjugate
treating
drug
preventing cancer
trop2 antibody
Prior art date
Application number
BR112021023901A
Other languages
English (en)
Inventor
Daisuke Okajima
Jonathan Greenberg
Satoru Yasuda
Takuma Iguchi
Tomonari Yamashita
Yutaka Noguchi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112021023901A2 publication Critical patent/BR112021023901A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, e, uso de um conjugado anticorpofármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer. a presente descrição se refere ao campo das preparações farmacêuticas, regimes de dosagem e administração de um conjugado anticorpo-fármaco (adc). mais especificamente, o adc é composto por um anticorpo antígeno de superfície celular anti-trofoblasto 2 (trop2) conectado por meio de um ligante a um agente anticâncer, como o inibidor de topoisomerase i.
BR112021023901A 2019-05-29 2020-05-28 Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer BR112021023901A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853970P 2019-05-29 2019-05-29
US201962896478P 2019-09-05 2019-09-05
PCT/IB2020/055078 WO2020240467A1 (en) 2019-05-29 2020-05-28 Dosage of an antibody-drug conjugate

Publications (1)

Publication Number Publication Date
BR112021023901A2 true BR112021023901A2 (pt) 2022-01-18

Family

ID=71083673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023901A BR112021023901A2 (pt) 2019-05-29 2020-05-28 Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer

Country Status (12)

Country Link
US (1) US20230270870A1 (pt)
EP (1) EP3976113A1 (pt)
JP (1) JP2022534725A (pt)
KR (1) KR20220015445A (pt)
CN (1) CN113939318A (pt)
AU (1) AU2020285681A1 (pt)
BR (1) BR112021023901A2 (pt)
CA (1) CA3142119A1 (pt)
IL (1) IL288485A (pt)
SG (1) SG11202112429PA (pt)
TW (1) TW202108180A (pt)
WO (1) WO2020240467A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550532A (ja) * 2020-12-18 2023-12-01 シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド Ｔｒｏｐ２を標的とする抗体薬物複合体、その製造方法及び使用
CN117425500A (zh) * 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗dll3抗体-药物缀合物
EP4351657A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CA3222269A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
KR20240091056A (ko) 2021-10-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 피리디진-3(2h)-온 유도체
CN118201941A (zh) 2021-10-29 2024-06-14 吉利德科学公司 Cd73化合物
WO2023089527A1 (en) 2021-11-18 2023-05-25 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023126823A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
WO2023138635A1 (zh) * 2022-01-18 2023-07-27 甘李药业股份有限公司 一种依喜替康衍生物-抗体偶联物及其医药用途
WO2023143387A1 (en) * 2022-01-26 2023-08-03 Beigene , Ltd. ANTI-DXd ANTIBODIES AND METHODS OF USE
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023201268A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating tumor antigen expressing cancers
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
TW202412859A (zh) 2022-07-28 2024-04-01 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及雙特異性檢查點抑制劑之組合
WO2024051762A1 (en) * 2022-09-07 2024-03-14 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-trop2/egfr antibodies and uses thereof
WO2024097812A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Therapy for treating bladder cancer
WO2024109840A1 (zh) * 2022-11-22 2024-05-30 康诺亚生物医药科技（成都）有限公司 稠环类化合物及其偶联物和用途
WO2024116094A1 (en) 2022-11-30 2024-06-06 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugates and dnmt inhibitors
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
JP2002060351A (ja) 2000-03-22 2002-02-26 Dai Ichi Seiyaku Co Ltd 水酸基を有する薬物を含むｄｄｓ化合物
EP1331266B1 (en) 2000-10-06 2017-01-04 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
BRPI0213846B8 (pt) 2001-11-01 2021-05-25 Uab Research Foundation composição que compreende um anticorpo que liga especificamente uma dr5 do receptor de trail e um ou mais agentes terapêuticos
ES2871905T3 (es) 2002-03-01 2021-11-02 Immunomedics Inc Inmunoconjugado que comprende anticuerpos de RS7 humanizados
US20080131428A1 (en) 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
HRP20221259T1 (hr) 2009-02-13 2022-12-09 Immunomedics, Inc. Imunokonjugati s intracelularnom vezom koja se može rascijepiti
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
CN103228673A (zh) 2010-05-17 2013-07-31 株式会社立富泰克 在体内具有抗肿瘤活性的抗人trop-2 抗体
WO2011155579A1 (ja) 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Ｔｒｏｐ－２抗体
BR112014011331A2 (pt) 2011-11-11 2017-04-25 Rinat Neuroscience Corp anticorpos específicos para trop-2 e seus usos
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
WO2015098099A1 (ja) * 2013-12-25 2015-07-02 第一三共株式会社 抗ｔｒｏｐ２抗体－薬物コンジュゲート
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
US11273155B2 (en) * 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
EP3673918A4 (en) * 2017-08-23 2021-05-19 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE PREPARATION AND ASSOCIATED LYOPHILIZATION
SG11202001514XA (en) * 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
BR112020003646A2 (pt) * 2017-08-31 2020-09-01 Daiichi Sankyo Company, Limited cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal.
CN114573699A (zh) * 2018-07-09 2022-06-03 启德医药科技（苏州）有限公司 滋养层细胞表面抗原2(trop2)特异性抗体
EP3831853A4 (en) * 2018-07-27 2022-06-01 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT
WO2020027100A1 (ja) * 2018-07-31 2020-02-06 第一三共株式会社 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
TW202019487A (zh) * 2018-08-06 2020-06-01 日商第一三共股份有限公司 抗體-藥物結合物及微管蛋白抑制劑之組合
KR20210102341A (ko) * 2018-12-11 2021-08-19 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 parp 저해제의 조합

Also Published As

Publication number Publication date
KR20220015445A (ko) 2022-02-08
WO2020240467A1 (en) 2020-12-03
SG11202112429PA (en) 2021-12-30
CA3142119A1 (en) 2020-12-03
TW202108180A (zh) 2021-03-01
AU2020285681A1 (en) 2022-01-27
IL288485A (en) 2022-01-01
US20230270870A1 (en) 2023-08-31
CN113939318A (zh) 2022-01-14
JP2022534725A (ja) 2022-08-03
EP3976113A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
BR112021023901A2 (pt) Conjugado anticorpo-fármaco anti-trop2, composição farmacêutica, método para tratar ou prevenir câncer, e, uso de um conjugado anticorpo-fármaco anti-trop2 na fabricação de um fármaco para o tratamento ou prevenção do câncer
BR112021017621A2 (pt) Composições e métodos de uso compreendendo substâncias com ações de plasticidade neural administradas em dosagens e formulações não psicodélicas/psicotomiméticas
EP4223316A3 (en) Improved antibody-oligonucleotide conjugate
ECSP14012676A (es) Compuestos de carbamato y preparación y uso de los mismos
BR112018067379A2 (pt) conjugado anticorpo-droga, composição, método para tratamento de um paciente que tem ou corre o risco de ter um câncer, para produzir o conjugado anticorpo-droga ou a composição, para determinar se um paciente será responsivo a um tratamento com o conjugado anticorpo-droga ou a composição, e, uso de um conjugado anticorpo-droga ou de uma composição.
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
BR112012022802A2 (pt) uso de um inibidor de erbb3, e, método de supressão de crescimento de uma célula e de um tumor de câncer de mama
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
PA8635501A1 (es) Uso de un anticuerpo para el tratamiento del lupus
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112012030658A2 (pt) formas de dosagem oral de bendamustina e uso terapêutico da mesma
Hou et al. Autophagy and tumour chemotherapy
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112023001956A2 (pt) Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer
BR112018076639A2 (pt) quimioterapias de combinação
UY28271A1 (es) Compuestos químicos
BR112020010856A8 (pt) Uso de conjugado de anticorpo anti-her2-fármaco no tratamento de carcinoma urotelial
EA201891575A1 (ru) Составы для лечения рака мочевого пузыря
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
CN105963637A (zh) 隐丹参酮联合姜黄素在制备肿瘤治疗药物中的应用
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças